Last reviewed · How we verify
IV Cyclophosphamide
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells.
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells. Used for Lymphomas and leukemias, Solid tumors (breast cancer, ovarian cancer, lung cancer), Severe autoimmune diseases (systemic lupus erythematosus, vasculitis).
At a glance
| Generic name | IV Cyclophosphamide |
|---|---|
| Also known as | Cytoxan, Neosar |
| Sponsor | Johns Hopkins University |
| Drug class | Alkylating agent |
| Target | DNA (non-specific alkylation) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
As a nitrogen mustard derivative, cyclophosphamide forms covalent bonds between DNA strands, disrupting DNA replication and transcription. This mechanism is particularly effective against rapidly dividing cancer cells and also suppresses immune cell proliferation, making it useful in both oncology and autoimmune conditions. The drug requires hepatic activation to its active metabolites.
Approved indications
- Lymphomas and leukemias
- Solid tumors (breast cancer, ovarian cancer, lung cancer)
- Severe autoimmune diseases (systemic lupus erythematosus, vasculitis)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Hemorrhagic cystitis
- Nausea and vomiting
- Alopecia
- Infertility (gonadal dysfunction)
- Secondary malignancies
- Immunosuppression and infection risk
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Cyclophosphamide CI brief — competitive landscape report
- IV Cyclophosphamide updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI